Danaher Corporation has announced a strategic partnership with AstraZeneca to develop and commercialize advanced diagnostic tests aimed at identifying patients who would most benefit from targeted precision medicine therapies. The initiative will be supported by the newly launched Danaher Centers for Enabling Precision Medicine and will initially focus on digital and computational pathology tools. The first diagnostic solution is set to be developed using technology from Leica Biosystems, a Danaher subsidiary known for its digital pathology platforms. Julie Sawyer Montgomery, Executive Vice President at Danaher, stated, “Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit.”
AstraZeneca emphasized the need for accurate diagnostics to support innovative treatments like antibody-drug conjugates. “Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics which can improve patient selection,” said Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca. Leica Biosystems plans to scale the developed tools for clinical use globally and has committed to open-access DICOM standards to enable greater interoperability. “With our global footprint and leading digital pathology platform, we expect to be able to deploy the tests developed with AstraZeneca to patients worldwide,” added Gustavo Perez-Fernandez, President of Leica Biosystems.
